Navigation Links
WEHI Spin-Out MuriGen Restructures G-CSF Antagonist Program With CSL
Date:10/27/2008

linic."

Dr Andrew Cuthbertson, Director of R&D at CSL said, "The G-CSF inflammatory disease project is an excellent example of the strength of Australian medical research. We look forward to a continuing collaboration with our academic colleagues as we take this program into early stage development."

About MuriGen Therapeutics

MuriGen Therapeutics is an Australian-based drug discovery and development company established by the Walter and Eliza Hall Institute of Medical Research and four of its leading scientists. MuriGen is building a portfolio of novel drugs for unmet medical needs across a number of therapeutic areas including arthritis, thrombocytopenia, inflammation, epilepsy and thalassemia. By leveraging its proprietary drug discovery platform, MuriGen Therapeutics is working towards the validation of novel drug targets that have the potential to provide significant benefits for researchers, health care practitioners, and patients. Further information about MuriGen Therapeutics can be found at http://www.murigen.com.au

About WEHI

The Walter and Eliza Hall Institute of Medical Research (WEHI) is one of the world's leading medical research centres. WEHI's international reputation has been built upon major contributions to immunology, haematology, cancer, malaria and autoimmune diseases, including diabetes, multiple sclerosis, coeliac disease and rheumatoid arthritis. Over many decades, advances and discoveries in these areas have led to significant benefits for patients throughout the world. WEHI is in the front line of the biotechnology revolution, using advances in genetics, bioinformatics and structural biology to help develop individualised therapies and more effective drugs. Further information about WEHI can be found at http://www.wehi.edu.au

Further information:

Dr Nick Samaras

Chief Executiv
'/>"/>

SOURCE Walter and Eliza Hall Institute
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. VaxGen Restructures Board of Directors
2. Genta Restructures Operations to Focus on Priority Initiatives
3. Progen Restructures Manufacturing and Drug Discovery Divisions
4. Kosan Restructures Workforce to Focus Resources on Lead Clinical Programs
5. CME LLC Restructures, Announces Its New Executive Management Team
6. Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs
7. VaxGen Further Restructures to Preserve Cash as It Pursues Strategic Initiatives
8. ChemoCentryx Advances Second Orally Available CCR9 Antagonist CCX025 Into Clinical Development
9. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
10. Sensitivity Enhancements to Monograms Trofile(TM) Assay Demonstrate Improved Power to Select Patients for CCR5 Antagonist Therapy
11. Brain Fitness Program Offers Hope for Breast Cancer Survivors Suffering From Chemobrain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 The Microcompetition with Foreign DNA ... disease. One of these latent viruses is the Epstein ... rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic ... by the theory, a study found that RA patients ... (1). , What is Microcompetition? , Dr. Hanan ...
(Date:1/15/2014)... Sunnyvale, CA (PRWEB) January 15, 2014 ... of high throughput research solutions, today announced that ... companies, has received delivery of Freeslate’s CM ... form screening. , Lupin, headquartered in Mumbai, ... quality, affordable generic and branded formulations and Active ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Date: Friday, ... p.m. , Location: Warrington Country Club, 1360 Almshouse Road, ... Foundation, the only national nonprofit organization solely dedicated to ... quality of life for those affected worldwide, will host ... Warrington Country Club in Warrington, Pa. , Each ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider ... major scientific, regulatory, business, and media events in ... , today announced its former associate Virginia Cox , ... office. Virginia Cox re-joins ... Commissioner for the Office of External Affairs at the U.S. ...
Breaking Biology Technology:Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Former FDA Associate Commissioner Returns To 3D Communications 2
... ... to market the TriPollar Technology- the most advanced 3rd generation Radio Frequency ... been clinically proven the world over to be safe and effective on ... enjoy visible results from the very 1st treatment. Long term results ...
... ... Ingelheim today announced results from the RE-COVER(TM) study investigating dabigatran etexilate ... warfarin in patients with acute VTE. Results of the trial ... and simultaneously published online in the New England Journal of ...
... , , Alberta Centre for Advanced ... & medical seminar, , EDMONTON, Dec. 4 /PRNewswire/ - Today ... like nanotechnology, biomaterials and microfluidics can play a powerful role ... health and improve the quality, cost and outcomes of patient ...
Cached Biology Technology:Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 2Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 4RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 5RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 6Alberta companies delivering new products to the health & medical marketplace 2
(Date:4/15/2014)... Goddard Space Flight Center in Greenbelt, Md., is ... project support staff. At Goddard, some of the ... place, and some of that cutting-edge innovation has ... , The Swedish Society for Anthropology and Geography ... a person who has shown excellence in the ...
(Date:4/15/2014)... mother-child pairs, researchers from the Bloomberg School of ... serotonin reuptake inhibitors (SSRIs), a frequently prescribed treatment ... with autism spectrum disorder (ASD) and developmental delays ... online edition of Pediatrics , analyzed data ... and population-based controls, where a uniform protocol was ...
(Date:4/15/2014)... Mo. University of Missouri researchers have previously shown ... motivated to exercise exists. In a new study, Frank ... Medicine, has found a potential link between the genetic ... speed at which mental maturation occurs. , For his ... either extreme activity or extreme laziness. Booth then put ...
Breaking Biology News(10 mins):Goddard scientist receives Vega Medal from King of Sweden 2Study: SSRI use during pregnancy associated with autism and developmental delays in boys 2Genetic pre-disposition toward exercise and mental development may be linked 2
... came word that a rare frog (Amolops tormotus) in ... produces very high-pitch ultrasonic sounds. Now scientists say that ... the sounds. , The findings, to appear in the ... case of an amphibian being able to communicate like ...
... at The University of Texas at Austin have developed a ... surrounds bacteria and plays a role in infection and immunity. ... the course of an infection, cloaking the bacteria from the ... sugars were too slow to catch these rapid changes. ...
... have discovered a new mechanism responsible for early left/right ... the left or right side of the body. ... the study of three different vertebrates (frogs, chickens and ... mechanism has been identified in left-right patterning in three ...
Cached Biology News:Rare Chinese frogs communicate by means of ultrasonic sound 2Rare Chinese frogs communicate by means of ultrasonic sound 3Scientists seek to unwrap the sweet mystery of the sugar coat on bacteria 2Forsyth scientists gain greater understanding of how embryos differentiate left from right 2Forsyth scientists gain greater understanding of how embryos differentiate left from right 3
Mouse CXCR3 Allophycocyanin MAb (Clone 220803)...
Request Info...
Recombinant Rat Leptin, Ultra Pure...
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Biology Products: